0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%
Last update at 2024-11-21T14:20:00Z
UK's Notable Stocks That May Be Trading Below Estimated Value October 2024
Fri 18 Oct 24, 06:03 AMUK Value Stocks That Might Be Priced Below Intrinsic Estimates In October 2024
Wed 16 Oct 24, 06:04 AM3 UK Stocks That Could Be Trading Below Estimated Value
Tue 15 Oct 24, 06:06 AM3 UK Stocks Estimated To Be Trading At Up To 42.1% Below Intrinsic Value
Mon 07 Oct 24, 06:02 AMSeptember 2024's UK Stock Picks For Possible Value Investing
Mon 30 Sep 24, 06:03 AMGlobalData And 2 UK Stocks Possibly Trading Below Fair Value
Thu 26 Sep 24, 06:02 AM3 UK Stocks Estimated To Be Trading At Discounts Of Up To 47%
Mon 23 Sep 24, 06:06 AM3 UK Stocks Estimated To Be Trading At Up To 44.5% Below Intrinsic Value
Thu 12 Sep 24, 06:08 AM3 UK Stocks Possibly Trading Below Their Intrinsic Value By Up To 46.2%
Tue 06 Aug 24, 07:04 AMHere's Why Ensign Group (ENSG) is a Strong Value Stock
Wed 19 Jul 23, 01:40 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 1.90M | 24.93M | 13.30M | 4.78M | 1.21M |
| Minority interest | -0.62600M | -0.41700M | -3.83000M | -4.40800M | -4.36800M |
| Net income | 1.56M | 14.34M | 9.79M | 3.92M | 0.36M |
| Selling general administrative | 13.02M | 12.24M | 15.88M | 11.75M | 5.42M |
| Selling and marketing expenses | 17.21M | 18.29M | 20.20M | 16.31M | 4.35M |
| Gross profit | 37.96M | 51.06M | 60.71M | 33.15M | 34.46M |
| Reconciled depreciation | 4.89M | 5.26M | 5.47M | 5.36M | 3.39M |
| Ebit | 3.13M | 24.38M | 14.23M | 6.09M | 1.52M |
| Ebitda | 8.80M | 31.11M | 20.53M | 11.45M | 4.91M |
| Depreciation and amortization | 5.66M | 6.73M | 6.29M | 5.36M | 3.39M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 3.13M | 24.38M | 14.23M | 6.09M | -0.25700M |
| Other operating expenses | 112.99M | 115.66M | 169.33M | 118.91M | 119.82M |
| Interest expense | 2.01M | 0.91M | 1.75M | 1.32M | 0.54M |
| Tax provision | 0.34M | 9.34M | 1.04M | 0.47M | 0.62M |
| Interest income | 0.73M | 1.47M | 0.82M | 0.94M | 0.21M |
| Net interest income | -0.60400M | 0.56M | -0.93400M | -0.13600M | -0.36400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.34M | 9.34M | 1.04M | 0.47M | 0.62M |
| Total revenue | 116.12M | 140.04M | 183.57M | 123.40M | 119.56M |
| Total operating expenses | 34.82M | 26.68M | 46.48M | 28.66M | 34.72M |
| Cost of revenue | 78.17M | 88.98M | 122.86M | 90.25M | 85.10M |
| Total other income expense net | -1.23900M | 0.56M | -0.93400M | -1.31600M | 1.47M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 0.87M | 14.76M | 11.48M | 3.27M | -0.32300M |
| Net income applicable to common shares | 0.24M | 14.34M | 9.79M | 3.92M | 0.36M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 175.18M | 193.16M | 200.11M | 173.83M | 128.88M |
| Intangible assets | 5.95M | 4.65M | 6.88M | 6.94M | 6.28M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 34.93M | 41.47M | 42.78M | 35.01M |
| Total liab | 61.18M | 69.03M | 81.34M | 69.41M | 45.88M |
| Total stockholder equity | 115.07M | 127.42M | 122.59M | 108.82M | 87.38M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.82M | 6.55M | 3.05M | 0.31M | 18.20M |
| Common stock | 1.32M | 1.32M | 1.32M | 1.32M | 1.22M |
| Capital stock | 1.32M | 1.32M | 1.32M | 1.32M | 1.22M |
| Retained earnings | -279.57900M | -279.88800M | -290.09000M | -299.39100M | -303.26400M |
| Other liab | 4.13M | 4.68M | 7.96M | 7.56M | 6.43M |
| Good will | 12.58M | 11.38M | 16.84M | 16.80M | 16.34M |
| Other assets | 3.98M | 5.11M | 7.64M | 5.13M | 4.66M |
| Cash | 35.16M | 65.33M | 50.58M | 40.58M | 20.81M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 51.29M | 57.89M | 64.27M | 52.76M | 38.95M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -25.17900M | -55.04700M | -33.85100M | -23.49800M | -14.95600M |
| Short term debt | 4.22M | 3.82M | 7.61M | 7.99M | 5.37M |
| Short long term debt | 2.23M | 1.63M | 5.37M | 5.92M | 5.37M |
| Short long term debt total | 9.98M | 10.28M | 16.72M | 17.09M | 5.86M |
| Other stockholder equity | 393.33M | 405.99M | 411.36M | 406.89M | 408.86M |
| Property plant equipment | 20.77M | 24.68M | 25.72M | 24.15M | 14.08M |
| Total current assets | 115.12M | 133.65M | 128.74M | 110.29M | 82.26M |
| Long term investments | - | - | - | 10.51M | 5.27M |
| Net tangible assets | 96.54M | 111.39M | 98.88M | 85.08M | 64.75M |
| Short term investments | 9.01M | 2.43M | 2.80M | 4.25M | 3.58M |
| Net receivables | 25.61M | 34.93M | 35.00M | 37.89M | 31.18M |
| Long term debt | 2.00M | 1.36M | 0.68M | 0.76M | 0.49M |
| Inventory | 34.46M | 30.95M | 33.89M | 22.67M | 22.86M |
| Accounts payable | 46.26M | 47.52M | 53.62M | 44.46M | 13.72M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -23.74700M | -19.44100M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 1.32M | 1.32M | 1.22M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 9.63M | 4.17M | 4.68M | 6.15M | 3.06M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 60.06M | 59.52M | 71.37M | 63.54M | 46.63M |
| Capital lease obligations | 5.74M | 7.29M | 10.68M | 10.41M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -16.34200M | -0.32500M | -1.90700M | 0.27M | 0.11M |
| Change to liabilities | 0.00000M | -5.35200M | 7.11M | 11.36M | -3.57900M |
| Total cashflows from investing activities | -16.34200M | 15.07M | -5.48100M | -2.58200M | 0.84M |
| Net borrowings | -0.74400M | -4.99500M | -3.30000M | -2.19700M | -0.36000M |
| Total cash from financing activities | -7.05000M | -4.93700M | -3.24900M | 15.48M | -0.30900M |
| Change to operating activities | - | -3.42900M | 2.21M | 0.42M | -0.20000M |
| Net income | 3.13M | 24.38M | 14.23M | 4.48M | 0.36M |
| Change in cash | -30.17500M | 14.76M | 9.99M | 19.77M | 2.63M |
| Begin period cash flow | 65.33M | 50.58M | 40.58M | 20.81M | 18.18M |
| End period cash flow | 35.16M | 65.33M | 50.58M | 40.58M | 20.81M |
| Total cash from operating activities | -2.78400M | 5.59M | 18.46M | 7.17M | 2.61M |
| Issuance of capital stock | 0.00000M | 0.06M | 0.05M | 17.68M | 0.05M |
| Depreciation | 4.89M | 5.26M | 5.47M | 5.36M | 3.39M |
| Other cashflows from investing activities | - | 0.00300M | 0.10M | 0.19M | -1.69400M |
| Dividends paid | 4.30M | 4.30M | 4.30M | 4.30M | - |
| Change to inventory | -3.25800M | 3.03M | -11.19800M | 1.39M | 0.35M |
| Change to account receivables | - | -2.05200M | 0.92M | -7.89600M | 4.82M |
| Sale purchase of stock | -1.32500M | - | 0.05M | 17.68M | 0.05M |
| Other cashflows from financing activities | 9.59M | 8.26M | 10.55M | 7.72M | 9.60M |
| Change to netincome | -1.01100M | -6.21000M | 4.15M | -7.37700M | -2.54000M |
| Capital expenditures | 4.47M | 3.29M | 3.71M | 2.21M | 3.59M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -6.90800M | -4.37300M | -0.96100M | 5.27M | 1.40M |
| Stock based compensation | 0.30M | 0.10M | 0.16M | 0.10M | 0.06M |
| Other non cash items | -4.19900M | -19.77300M | -0.44600M | -8.04700M | -2.59800M |
| Free cash flow | -7.25200M | 2.30M | 14.74M | 4.96M | -0.97900M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BVC Batm Advanced Communications Ltd |
- -% | 19.45 | - | - | 0.74 | 0.99 | 0.56 | 8.37 |
| CTEC ConvaTec Group PLC |
-2.4 1.03% | 230.60 | 81.73 | 20.24 | 2.39 | 3.93 | 2.93 | 15.13 |
| AMS Advanced Medical Solutions Group plc |
5.50 2.76% | 204.50 | 23.56 | 22.62 | 3.54 | 1.93 | 3.15 | 11.29 |
| TSTL Tristel |
- -% | 440.00 | 51.11 | 37.04 | 6.08 | 7.11 | 5.94 | 27.03 |
| SPEC Inspecs Group plc |
- -% | 54.00 | - | 12.29 | 0.42 | 0.80 | 0.60 | 9.42 |
BATM Advanced Communications Ltd., together with its subsidiaries, develops, produces, and markets real-time technologies in Israel, the United States, and Europe. It operates through two segments, Networking and Cyber, and Bio-Medical. The Networking and Cyber segment is involved in the research and development, production, and marketing of data communication products, including network function virtualization, edge computing, carrier ethernet and MPLS access solutions, cyber network monitoring, and network encryption. This segment also offers software services, such as training and technical support, laboratory service and maintenance; and construction contracts. The Bio-Medical segment offers molecular biology diagnostics; and solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications. This segment also administers testing services; and distributes diagnostic equipment and medical supplies of various brands. The company was incorporated in 1992 and is headquartered in Hod Hasharon, Israel.
Neve Ne?eman Ind. Area, Hod HaSharon, Israel, 4524075
| Name | Title | Year Born |
|---|---|---|
| Dr. Zvi Marom | Founder, CEO & Exec. Director | 1955 |
| Mr. Moti Nagar | CFO & Exec. Director | NA |
| Mr. Ariel Efrati | COO of Telecom Division & CEO of Telco Systems | NA |
| Mr. Yair Livneh | Company Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...